What is the recommended fexofenadine dosage for allergic rhinitis or chronic urticaria in adults and children, and how should it be adjusted in renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fexofenadine Dosing Recommendations

For adults and children ≥12 years with allergic rhinitis or chronic urticaria, use fexofenadine 60 mg twice daily or 180 mg once daily; for children 6-11 years, use 30 mg twice daily 1.

Standard Dosing by Indication and Age

Seasonal Allergic Rhinitis

Adults and children ≥12 years:

  • 60 mg twice daily OR 180 mg once daily 1
  • Both regimens demonstrate equivalent efficacy 2
  • Onset of symptom relief occurs within ≤2 hours 2

Children 6-11 years:

  • 30 mg twice daily 1, 3
  • This dose effectively reduces all seasonal allergic rhinitis symptoms including nasal congestion 3

Children 2-5 years:

  • 30 mg twice daily (based on safety data, though not FDA-approved for this age) 4
  • Well tolerated with good safety profile in this age group 4

Chronic Idiopathic Urticaria

Adults and children ≥12 years:

  • 60 mg twice daily OR 180 mg once daily 1
  • For chronic urticaria specifically, 180 mg once daily is the optimal dose 5

Children 6-11 years:

  • 30 mg twice daily 1

Renal Impairment Adjustments

Critical adjustment required: Fexofenadine is primarily renally excreted and requires dose reduction in renal dysfunction 6, 1.

Adults and children ≥12 years with decreased renal function:

  • Start with 60 mg once daily (instead of twice daily or 180 mg) 1

Children 6-11 years with decreased renal function:

  • Start with 30 mg once daily (instead of twice daily) 1

Specific renal impairment guidance:

  • Acrivastine should be avoided in moderate renal impairment (creatinine clearance 10-20 mL/min) 6
  • Cetirizine, levocetirizine, and hydroxyzine doses should be halved in renal impairment 6
  • These agents should be avoided in severe renal impairment (creatinine clearance <10 mL/min) 6

Key Clinical Advantages

Fexofenadine is preferred among second-generation antihistamines because:

  • No sedation at any dose, including supratherapeutic doses up to 240 mg/day 7, 8, 9
  • No cardiac effects or QT prolongation, even when combined with erythromycin or ketoconazole 2, 8
  • No drug-drug interactions via cytochrome P450 system 6
  • Improves quality of life more than loratadine to a clinically meaningful extent 2

Administration Details

  • Take with water 1
  • Can be taken without regard to meals, though food may improve GI tolerability 1
  • For young children unable to swallow tablets, capsule contents can be mixed with applesauce (approximately 10 mL) 4

Important Caveats

Hepatic impairment: While fexofenadine is not extensively metabolized, use with caution in severe hepatic impairment 6. Unlike mizolastine (contraindicated) or alimemazine (hepatotoxic), fexofenadine has no specific hepatic contraindications but general caution is advised.

Pregnancy: Fexofenadine has no reports of increased congenital malformations and negative animal studies, though no formal epidemiologic studies exist 7. The accumulated safety data for second-generation antihistamines including fexofenadine are comparable to first-generation agents 7.

Comparative efficacy: Among second-generation antihistamines, no single agent demonstrates conclusively superior efficacy 7. Fexofenadine shows equivalent efficacy to loratadine and cetirizine for seasonal allergic rhinitis 2.

References

Research

Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2004

Research

Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Research

The systemic safety of fexofenadine HCl.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1999

Research

Pharmacology of antihistamines.

Indian journal of dermatology, 2013

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.